Document Type : Original research articles
Authors
1
Department of registration of the biological products, Egyptian Drug Authority (EDA), Dokki, Giza, Egypt
2
Department of Medical Molecular Genetics, National Research Center (NRC), Dokki, Giza, Egypt
3
Department of cardiac surgery, National Heart Institute (NHI), Giza, Egypt.
4
Department of Biochemistry and Molecular Biology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.
Abstract
Coronary heart disease (CHD), as well as diabetes illness, remain the cause of mortality worldwide; hence, founding new biomarkers measurable in the initial stage of illness is necessary to accelerate treatment efficiency. Recently evidence has demonstrated alterations in miRNA levels associated with deregulated gene expression in diabetes and CHD. This case-control study investigates the probable effect of miR-146a rs2910164 C /G polymorphism in diabetes and atherosclerotic cardiovascular disease in Egyptian patients. The study comprised 210 individuals, including 70 CHD patients without diabetes, 70 CHD patients with diabetes, and 70 healthy controls, of Egyptian origin. Anthropometric and blood biochemical parameters were measured as well genetic analysis for rs2910164 C/G polymorphism was performed for all subjects using TaqMan real-time PCR assay.
Our results revealed that; the biomedical parameters have a significant correlation between CHD with and without diabetes patients and healthy controls with a p-value <0.05. Analyses of genotype distribution for (rs2910164 C/G) revealed a significant association in both CHD with and without diabetes and control (odd ratio= 1.56, confidence interval (CI 95 %) = (0.06-0.63)) and (odd ratio= 0.88, (CI 95 %) = (0.83-0.92)) respectively. The current study’s findings indicated that the selected polymorphism, miR-146a rs2910164 could represent a useful biomarker for susceptibility to CHD and diabetes in the Egyptian people.
Keywords
)
View on SCiNiTO